Manuel Carrondo | Vice President
IBET

Manuel Carrondo, Vice President, IBET

Chemical Engineer, 1971, Univ. Porto; Master of Sciences (1975) and Philosophy Doctor (1979) Environmental Engineering, Imperial College of Science and Technology, U. London; Habilitation, Biochemical Engineering (1991), Univ. Nova de Lisboa.

Full Professor, Chemical and Biochemical Engineering, Faculty of Sciences and Technology, Univ. Nova de Lisboa (1995-present). Founder (1988) and earlier president and CEO (currently Director) of IBET – Institute for Experimental and Technological Biology (www.ibet.pt), founder and board member of the Portuguese Academy of Engineering (1998-2001) and board member of the Euro CASE (Council on Applied Science and Engineering) (1998-2001), chairman of the European Society of Animal Cell Technology (ESACT) (1997-2001) and of Medical Biotechnology Section of the European Federation of Biotechnology (EFB) (1999-2001), member and Vice- Chairman of the External Advisory Group “Cell Factory” (Research Directorate General, European Commission) (1998-2002), Portuguese High Level Representative at EUREKA Programme (1993-1996), member of the Advisory Board of Max-Planck Institute for Dynamics of Complex Technical Systems, Magdeburg (2008-...), KGI-Keck Graduate Institute, Claremont, California (2007-...), CEVEC Pharmaceuticals, Köln (2007-...), PBS Biotech, California (2009-…), CNIC - Spanish National Center for Cardiovascular Research Carlos III, Spain (2011-…), Masthercells - Manufacturing Synergies for Therapeutic Cells, Belgium (2012-…) and Alloksys - Life Sciences BV, Holland (2012-…).

Meeting Chairman of the ESACT 14th Meeting “Animal Cell Technology: From Vaccines to Genetic Medicine”, Vilamoura, May 1996 and of the “3rd Recombinant Protein Production Meeting: A comparative view on host physiology", Tavira-Algarve (Portugal), November 2004. Visiting Professor at Carnegie-Mellon Univ. (1981), Massachusetts Institute of Technology - MIT (1988), Gesellschaft für Biotechnologische Forschung (1989 and 1993).
Supervised twenty-nine Ph.D. students (thesis defended) and published over two hundred papers in refereed international journals; Associate-Editor of Journal of Biotechnology, member of the editorial board of Biotechnology and Bioengineering, Current Gene Therapy and Biotechnology Letters; referee of Biotechnology Progress, Cytotechnology, Applied Microbiology and Biotechnology, Enzyme and Microbial Biotechnology.

Key areas of research interest: Animal Cell Technology and its application for human and animal health. Therapeutic and diagnostic recombinant proteins, including fusion proteins; virus like particles and pseudo viruses as vaccination agents and viruses (retro-, adeno-, lenti-) as deliverables for gene therapy; cell therapies and stem cells. cGMP pilot plant scale-up and production development of biopharmaceuticals.

Appearances:



Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 16:40

Viral DSP development, stem cell and cell therapy purification and concentration

  • GMP and coping with the complexity of purifying new format products
  • Tackling the challenges of variability and maintaining high standards of quality during purification
  • Ensuring high purity and lack of contamination when preparing product release

back to speakers

World Advanced Therapies & Regenerative Medicine Congress

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com